SKYE - Skye Bioscience posts preclinical data from eye disease treatment study

Skye Bioscience (SKYE) announces preclinical data showing that THCVHS, the company’s novel THC prodrug, showed no signs of irritation of the eye using an in vitro assay, the EpiOcular  MTT ET-50.The EpiOcular  MTT ET-50 risk assessment assay determines the effective time when a material causes a 50% reduction in the viability of tissue being assessed.The preclinical findings from the study showed that THCVHS achieved the lowest possible ranking of mild/non-irritating at each dose range (0.5-2.0%) anticipated to be used in Skye’s upcoming Phase 1 study.EpiOcular is an in vitro eye irritation test alternative to animal (in vivo) testing using human epithelial cells in a 3D model which closely mimics the histological, morphological, biochemical, and physiological properties of the human corneal epithelium.The company expects to report topline data from its first-in-human Phase 1 study of THCVHS for the treatment of glaucoma in early 2022.

For further details see:

Skye Bioscience posts preclinical data from eye disease treatment study